KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Other Operating Expenses (2017 - 2025)

Travere Therapeutics (TVTX) has disclosed Other Operating Expenses for 15 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses fell 1.47% year-over-year to $2.6 million, compared with a TTM value of $10.3 million through Dec 2025, down 85.83%, and an annual FY2025 reading of $10.3 million, down 85.83% over the prior year.
  • Other Operating Expenses was $2.6 million for Q4 2025 at Travere Therapeutics, up from $1.6 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $66.7 million in Q1 2024 and bottomed at -$30.0 million in Q4 2022.
  • Average Other Operating Expenses over 5 years is $2.7 million, with a median of $1.8 million recorded in 2024.
  • The sharpest move saw Other Operating Expenses surged 1953.62% in 2021, then crashed 274.05% in 2022.
  • Year by year, Other Operating Expenses stood at -$25.0 million in 2021, then dropped by 19.9% to -$30.0 million in 2022, then skyrocketed by 115.21% to $4.6 million in 2023, then tumbled by 43.23% to $2.6 million in 2024, then fell by 1.47% to $2.6 million in 2025.
  • Business Quant data shows Other Operating Expenses for TVTX at $2.6 million in Q4 2025, $1.6 million in Q3 2025, and $1.5 million in Q2 2025.